Skip to main content

Principal Scientist, ADME-Novel Modalities

Requisition ID: PHA001537

Merck & Co., Inc. Kenilworth, N.J., U.S.A. known as Merck in the United States and Canada, is a global health care leader with a diversified portfolio of prescription medicines, vaccines and animal health products. The difference between potential and achievement lies in the spark that fuels innovation and inventiveness; this is the space where Merck has codified its legacy for over a century . Merck's success is backed by ethical integrity, forward momentum, and an inspiring mission to achieve new milestones in global healthcare.

Merck is on a quest for cures and is committed to being the world's premier, most research-intensive biopharmaceutical company. Today, we're doubling down on this goal. Merck Research Laboratories is a true scientific research facility of tomorrow, and will take Merck's leading discovery capabilities and world-class small molecule and biologics R&D expertise to create breakthrough science that radically changes the way we approach serious diseases.

The Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM) function of MRL in Palo Alto/South San Francisco is seeking a dynamic and collaborative scientist for the Absorption, Distribution, Metabolism and Excretion (ADME) group. The Principal Scientist will be a member of the function providing expertise as a key component of the multi-disciplinary drug discovery effort in South San Francisco, with a focus on supporting preclinical development of therapeutics of various modalities through integrated understanding of drug disposition and pharmacology. Therapeutic areas may include immunology and oncology, cardiovascular and metabolic disease, and ophthalmology.

The responsibilities of the Principal Scientist will be to work within teams of highly collaborative scientists to contribute to the design, implementation, and analysis of in vitro and in vivo studies to understand the impact of disease biology and pharmacologic response on drug disposition. The candidate should be an experienced industrial scientist with a track record of designing and implementing appropriate assays and strategy to support the discovery and development of biologics, vaccines, and other modalities. The Principal Scientist should be able to independently forecast potential program derailers in regards to overall drug disposition and implement the appropriate PPDM strategy to derisk potential liabilities to ensure efficient program progression and/or decision making. The candidate should be well versed in immunology and up to date with current state of the art analytical techniques for quantiation and characterization of immunologic response and drug disposition. The Principal Scientist must be able to work collaboratively in a fast-paced environment and have excellent scientific, interpersonal and communication skills.

The ideal candidate will have an indepth understanding of ADME and pharmacokinetic principles that impact the disposition and response of immunologic therapies. Experience with various drug modalities across therapeutic areas desired. The candidate should have have experience with Phoenix, Berkeley Madonna, Watson, MATLAB or similar software.

Qualifications

Education Minimum Requirement:

• PhD. in Immunology, Pharmaceutical Sciences, Pharmacology, Computational Biology, Biomedical Engineering, Biochemistry, or related field.

Required Experience and Skills:

• 8 + years of combined industry and/or postdoctoral experience in relevant field with focus on immunologic response and drug disposition.

• Demonstrated experience leading ADME/PK/BA support of discovery or development programs in the biologics and vaccine (oncology) space.

• Experienced in development and implementation of analytical assays for the quantitation and characterization of immunologic response.

• Experienced in integrating preclinical ADME, PK, and pharmacology for establishing exposure-response relationships and enabling PK/PD modeling efforts to guide engineering and set anticipated therapeutic profile boundaries.

• Contribution (strategy and results) to preclinical data package to enable implementation of appropriate trasltional strategies for lead candidate selection and FIH dose projections.

Preferred Experience and Skills:

• Experience with discovery support of small molecules and other therapeutic modalities.

• Experience with preclinical development of protein therapeutics

Your role at Merck is integral to helping the world meet new breakthroughs that affect generations to come, and we're counting on your skills and inventiveness to help make meaningful contributions to global medical advancement. At Merck, we're inventing for life.

If you need assistance and/or a reasonable accommodation due to a disability during the application or the recruiting process, please send a request to staffingaadar@merck.com.

Search Firm Representatives Please Read Carefully:

Merck & Co., Inc. is not accepting unsolicited assistance from search firms for this employment opportunity. Please, no phone calls or emails. All resumes submitted by search firms to any employee at Merck via email, the Internet or in any form and/or method without a valid written search agreement in place for this position will be deemed the sole property of Merck. No fee will be paid in the event the candidate is hired by Merck as a result of the referral or through other means.

For more information about personal rights under Equal Employment Opportunity, visit:

EEOC Poster

EEOC GINA Supplement

OFCCP EEO Supplement

Merck is an equal opportunity employer, Minority/Female/Disability/Veteran - proudly embracing diversity in all of it's manifestations.

Job: Pharmacokinetics/Drug Metab
Other Locations:
Employee Status: Regular
Travel: Yes, 10 % of the Time
Number of Openings: 1
Shift (if applicable): N/A
Hazardous Materials: Yes; Not specified
Company Trade Name: Merck

Nearest Major Market: San Francisco
Nearest Secondary Market: Oakland

Principal Scientist, ADME-Novel Modalities

South San Francisco, CA
Full Time

Published on 07/13/2019